Pfizer announces IES analysis of Aromasin in breast cancer recurrence

NewsGuard 100/100 Score
Dec 11 2009

Pfizer today announced results from an exploratory analysis of the Intergroup Exemestane Study (IES) at a median follow-up of 91 months in estrogen-receptor positive (ER+) or estrogen-receptor unknown (ER-unknown) women that looked at breast cancer free survival (BCFS) and censored deaths that occurred prior to breast cancer relapse.

These data showed that women who switched to Aromasin® (exemestane tablets) after 2.5 years of tamoxifen experienced a 19 percent reduction in risk of breast cancer recurrence (BCFS)>

Source:

Pfizer

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , , , , , , , , , , , ,

Comments (0)

Suggested Reading

New microfluidic device improves the separation of tumor cells and clusters from malignant effusions
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis
New cancer projections show increased prostate cases by 25% in 2050, despite prevention efforts
Innovative breast cancer treatment sequence yields positive results
UCLA study finds pre-surgery immunotherapy safe for pancreatic cancer patients
Breakthrough imaging method enhances precision in prostate cancer treatment
Linking lifestyle to longevity: How diet and hypertension sway risks for heart disease and cancer
NCCN 2024 Annual Conference focuses on practical applications for improving cancer care

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Study reveals vascular health disparities between Black and white men with prostate cancer diagnosis